|Bid||3.2600 x 900|
|Ask||3.3800 x 1000|
|Day's Range||3.1500 - 3.4000|
|52 Week Range||2.1500 - 6.2900|
|Beta (5Y Monthly)||2.17|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 04, 2021 - Aug 09, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.80|
Galmed Pharmaceuticals (GLMD) is a clinical-stage biopharmaceutical company focused on developing Aramchol, a stearoyl-coenzyme A desaturase‑1 (SCD1) modulator that targets the liver. Aramchol is a novel oral therapy for the treatment of Non-alcoholic Steatohepatitis (NASH), a type of fatty liver disease and fibrosis. The company, in collaboration with the Hebrew University, is also developing Amilo-5MER, a 5 amino acid synthetic peptide. Synthetic peptides, when bound to a carrier protein, can
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, an oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH and fibrosis, reports financial results for the three months ended March 31, 2021. The Company will host a conference call and webcast at 08:30 ET today.
NEW YORK, NY / ACCESSWIRE / May 13, 2021 / Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 13, 2021 at 8:30 AM Eastern Time.